You are here

Servier

Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

Pharmaceutical Business Review

liposomal irinotecan

pancreatic cancer

Flag link:

Servier, armed with Shire cancer drugs, builds out vision for U.S. future

Servier, armed with Shire cancer drugs, builds out vision for U.S. future

Fierce Pharma

Flag link:

Amgen, Servier heart failure drug clears trial hurdle

Amgen, Servier heart failure drug clears trial hurdle

PM Live

Omecamtiv Mecarbil

clinical trials

Flag link:

Servier and Oncodesign announce Parkinson’s R&D tie-up

Servier and Oncodesign announce Parkinson’s R&D tie-up

Pharmaforum

Parkinson's Disease

Flag link:

Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Pharmaceutical Business Review

heart failure with reduced ejection fraction

Omecamtiv Mecarbil

Flag link:

FDA approves Servier's ALL therapy, acquired in Shire deal

FDA approves Servier's ALL therapy, acquired in Shire deal

BioCentury

Flag link:

Servier drops GeNeuro’s multiple sclerosis drug after midphase miss

Servier drops GeNeuro’s multiple sclerosis drug after midphase miss

Fierce Biotech

multiple sclerosis

Flag link:

Phase III Trial Data Demonstrates Significant Overall Survival Benefit of Lonsurf (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer

Phase III Trial Data Demonstrates Significant Overall Survival Benefit of Lonsurf (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer

CP Wire

Taiho Pharmaceutical

Flag link:

Phase III Trial Data Demonstrates Significant Overall Survival Benefit of Lonsurf (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer

Taiho Pharmaceutical

Flag link:

Servier opens Kendall Square site, plans Chinese office to access external innovation

Servier opens Kendall Square site, plans Chinese office to access external innovation

Fierce Biotech

Flag link:

Shire's oncology exit weighs on potential Takeda bid

Shire's oncology exit weighs on potential Takeda bid

Biopharma Dive

Flag link:

Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one

Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one

Endpoints

Flag link:

Servier, Pfizer get FDA OK to start US testing of an off-the-shelf CAR-T from Cellectis

Servier, Pfizer get FDA OK to start US testing of an off-the-shelf CAR-T from Cellectis

Endpoints

acute lymphocytic leukemia

Flag link:

Servier Joins Hands With Intarcia Therapeutics To Develop Implantable Diabetic Pump

Servier Joins Hands With Intarcia Therapeutics To Develop Implantable Diabetic Pump

Bidness Etc.

Flag link:

Pharmacyclics, Servier call it quits on a cancer drug

Pharmacyclics, Servier call it quits on a cancer drug

Fierce Biotech

Flag link:

SIGNIFY Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug

SIGNIFY Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug

Forbes

clinical trials

Flag link:

Servier to Teva Fined $582.2 Million on Generic Delays

Servier to Teva Fined $582.2 Million on Generic Delays

Bloomberg

Teva Pharmaceutical

Flag link:

Galapagos inks $367M deal in back-ended discovery pact with Servier

Galapagos inks $367M deal in back-ended discovery pact with Servier

Fierce Biotech

Flag link:

Servier Denies Concealing Risk Of Diabetes Drug

Servier Denies Concealing Risk Of Diabetes Drug

Pharmalot

Flag link: